文 献 1）Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015; 98(1): 19-24. 2）Mosch R, van der Lee M, Guchelaar HJ, Swen JJ. Pharmacogenetic Panel Testing: A review of current practice and potential for clinical implementation. Annu Rev Pharmacol Toxicol 2025; 65(1): 91-109. 3）Yamamoto N, Tanno Y, Tanaka Y, Hira D, Terada T, Saito Y et al. Development of novel mass spectrum-based assay for simultaneous detection of 36 variants in the 14 pharmacogenetic genes for the Japanese population. Biol Pharm Bull 2023; 46(3): 511-6. 4）Genes-Drugs. Clinical Pharmacogenetics Implementation Consortium (CPIC®) [https://cpicpgx.org/genes-drugs/ (accessed 2025-10-31)] 5）Lin XB, Li ZW, Yan M, Zhang BK, Liang W, Wang F, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol 2018; 84(7): 1587-97. 6）Campagne O, Mager DE, Tornatore KM. Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities? J Clin Pharmacol 2019; 59(3): 309-25. 7）Takahashi R, Itohara K, Nakagawa S, Katada Y, Sugimoto M, Umemura K, et al. Model-informed d o s i n g o p t i m i z a t i o n o f t a c r o l i m u s f o r concomitant administration with itraconazole to Japanese lung transplant recipients. Ther Drug Monit 2025; 47(2): 248-57. 8）Hennig S, Wainwright CE, Bell SC, Miller H, F r i b e r g L E , C h a r l e s B G . P o p u l a t i o n pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45(11): 1099-114. 9）Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526(7573): 343-50. 10）Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent a d v e r s e d r u g r e a c t i o n s : a n o p e n - l a b e l , multicentre, controlled, cluster-randomised crossover implementation study. Lancet 2023; 401(10374): 347-56.11）Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, et al. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 2020; 152: 105448.12）Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther 2021; 109(6): 1668-76.13）Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 2010; 69(6): 593-7.14）Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 2007; 46(8): 681-96. 15）Itohara K, Yano I, Nakagawa S, Sugimoto S, Hirai M, Yonezawa A, et al. Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics. Clin Transl Sci 2022; 15(11): 2652-62.移植患者に対する薬物動態関連遺伝子多型の先制的網羅的解析163
元のページ ../index.html#179